PE20011079A1 - Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, y composiciones que los comprenden - Google Patents

Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, y composiciones que los comprenden

Info

Publication number
PE20011079A1
PE20011079A1 PE2001000125A PE2001000125A PE20011079A1 PE 20011079 A1 PE20011079 A1 PE 20011079A1 PE 2001000125 A PE2001000125 A PE 2001000125A PE 2001000125 A PE2001000125 A PE 2001000125A PE 20011079 A1 PE20011079 A1 PE 20011079A1
Authority
PE
Peru
Prior art keywords
alkyl
preparation
carboxyl acid
alkenyl
substituted
Prior art date
Application number
PE2001000125A
Other languages
English (en)
Inventor
Werner Englberger
Michael Przewosny
Matthias Gerlach
Corinna Maul
Elke Reissmuller
Petra Bloms-Funke
Utz-Peter Jagusch
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20011079A1 publication Critical patent/PE20011079A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE ACIDO 1,2,3,4-TETRAHIDROQUINOLIN-2-CARBOXILICO SUSTITUIDOS DE FORMULA I DONDE R1 Y R2 SON (CH2)n, HC=CH-CH2, HC=CH-CH2-CH2, ENTRE OTROS; n ES 3-10; R3 ES H, ALQUILO C1-C18, ALQUENILO C2-C18, ALQUINILO C1-C18, ENTRE OTROS; R4 ES R4a, ZR4a; Z ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6; R4a ES H, ALQUILO C1-C12, ALQUENILO C2-C12, ALQUINILO C1-C12, COR9, ENTRE OTROS; R9 ES H, ALQUILO C1-C10, ALQUENILO C2-C10, ALQUINILO C1-C10, ENTRE OTROS; R5-R8 SON H, F, Cl, Br, I, CN, NO2, ALQUILO C1-C10, ALQUENILO C2-C10, ALQUINILO C2-C10, OR14, ENTRE OTROS; R14 ES H, ALQUILO C1-C10, ALQUENILO C2-C10, ALQUINILO C2-C10, ENTRE OTROS; R5 Y R6, R6 Y R7, R7 Y R8 FORMAN =CR18-CH=CH-CH=, =CH-CR18=CH-CH=; R18 ES H, F, Cl, Br, I, OH, ALQUILO C1-C10, ALQUENILO C2-C10, ALQUINILO C2-C10; CUANDO R1 Y R2 FORMAN -CH=CH-CH2 O GRUPO A; Y R3 ES (-)P-MENTAN-3-OL (MENTOL O BORNEOL) SIMULTANEAMENTE R7 NO ES Cl Y R5, R6, R8 SON H; ENTRE OTRAS CONDICIONES. SON COMPUESTOS PREFERIDOS 7,9-DICLORO-3a,4,5,9b-TETRAHIDRO-3H-CICLOPENTA[c]-QUINOLIN-4-CARBOXILATO DE ETILO; 8-CLORO-3a,4,5,9b-TETRAHIDRO-3H-CICLOPENTA[c]-QUINOLIN-4-CARBOXILATO DE ETILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON ANTAGONISTAS DE NMDA Y TIENEN EFECTO ANALGESICO, PARA EL TRATAMIENTO DEL DOLOR, MIGRANA, INCONTINENCIA URINARIA, PRURITO, EPILEPSIA, ESQUIZOFRENIA
PE2001000125A 2000-02-07 2001-02-06 Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, y composiciones que los comprenden PE20011079A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10005302A DE10005302A1 (de) 2000-02-07 2000-02-07 Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate

Publications (1)

Publication Number Publication Date
PE20011079A1 true PE20011079A1 (es) 2001-12-29

Family

ID=7630076

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000125A PE20011079A1 (es) 2000-02-07 2001-02-06 Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, y composiciones que los comprenden

Country Status (16)

Country Link
US (1) US6699877B2 (es)
EP (1) EP1254118B1 (es)
JP (1) JP2003522758A (es)
AR (1) AR029795A1 (es)
AT (1) ATE309220T1 (es)
AU (2) AU2679401A (es)
CA (1) CA2416343A1 (es)
CO (1) CO5271673A1 (es)
DE (2) DE10005302A1 (es)
DK (1) DK1254118T3 (es)
ES (1) ES2250345T3 (es)
HU (1) HUP0301080A3 (es)
MX (1) MXPA02007661A (es)
NZ (1) NZ521088A (es)
PE (1) PE20011079A1 (es)
WO (1) WO2001058875A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10124953A1 (de) * 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
DE10202864A1 (de) 2002-01-24 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten 1,2.3,4-Tetrahydrochinolin 2-carbonsäuren
EP1541560A4 (en) * 2002-08-01 2007-03-21 Kaken Pharma Co Ltd NEW TETRAHYDROCHINOLINE DERIVATIVES
DE10236910A1 (de) * 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
DE10304950A1 (de) * 2003-02-06 2004-08-19 Grünenthal GmbH Herstellung von Tetrahydrochinolinbenzofuranen
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
AU2004271932A1 (en) * 2003-08-13 2005-03-24 Oscient Pharmaceuticals Antibiotic cycloalkyltetrahydroquinoline derivatives
FR2864535B1 (fr) * 2003-12-24 2006-12-22 Merck Sante Sas Derives acides de quinoline et leurs applications en therapeutique
JP2008543726A (ja) 2005-02-24 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置のためのｐｇｄ２受容体アンタゴニスト
US20090203726A1 (en) * 2007-11-30 2009-08-13 Maxthera Inc. Substituted tetrahydroquinolines as antibacterial agents
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
WO2021209689A1 (en) * 2020-04-17 2021-10-21 Helsingin Yliopisto Compounds and compositions for treating sweet potato against sweet potato pathogenic viruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL93610A0 (en) * 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
US5605906A (en) * 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
US5925527A (en) * 1997-02-04 1999-07-20 Trega Biosciences, Inc. Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
JP3573679B2 (ja) * 2000-03-13 2004-10-06 独立行政法人 科学技術振興機構 高分子固定化α−イミノエステル

Also Published As

Publication number Publication date
US6699877B2 (en) 2004-03-02
JP2003522758A (ja) 2003-07-29
DE50107988D1 (de) 2005-12-15
MXPA02007661A (es) 2002-12-13
WO2001058875A2 (de) 2001-08-16
NZ521088A (en) 2004-05-28
ATE309220T1 (de) 2005-11-15
US20030087926A1 (en) 2003-05-08
DE10005302A1 (de) 2002-01-17
CA2416343A1 (en) 2001-08-16
AU2679401A (en) 2001-08-20
CO5271673A1 (es) 2003-04-30
ES2250345T3 (es) 2006-04-16
HUP0301080A2 (hu) 2003-08-28
DK1254118T3 (da) 2006-03-20
AR029795A1 (es) 2003-07-16
HUP0301080A3 (en) 2010-04-28
EP1254118B1 (de) 2005-11-09
EP1254118A2 (de) 2002-11-06
WO2001058875A3 (de) 2002-01-24
AU2001226794B2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
PE20011079A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, y composiciones que los comprenden
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
Valentino et al. Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists
US5760023A (en) Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
RU2095062C1 (ru) Блокатор синдрома отмены, являющегося результатом привыкания к чрезмерному потреблению лекарств или веществ, вызывающих привыкание, фармакологическая композиция на его основе и способ облегчения или предотвращения синдрома отмены
RU2007137649A (ru) 2-(4-оксо-4н-хиназолин-3-ил)ацетамиды и их использование в качестве вазопрессин v3 антагонистов
PE10997A1 (es) NUEVOS DERIVADOS DE [3-(4-FENILPIPERACIN-1-i1)PROPILAMINO]-PIRIDINA, PIRIMIDINA Y BENCENO COMO ANTAGONISTAS DE a1-ADRENOCEPTORES, SUS EMPLEOS COMO AGENTES TERAPEUTICOS Y LOS METODOS PARA SU PREPARACION
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
BRPI0618891A2 (pt) composições farmacêuticas
NZ525700A (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
CO5150235A1 (es) Agentes tiromimetricos antiobesidad roaceticos que los contiene
YU60696A (sh) Dihidropirimidini i njihova primena
MX2007012300A (es) Uso de nefopam y analogos del mismo para el tratamiento de un sindrome caracterizado por dolor cronico y fatiga.
PE20081579A1 (es) Derivados de benzamida como agonistas del receptor
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
AR070810A1 (es) Derivados de 1- bencil-3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 cx3cr1 y p40
PE20061049A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida como antagonistas del receptor de vanilloides tipo 1 (vr1)
PE20030739A1 (es) Antagonistas del receptor de adenosina a2a
BR0016635A (pt) Moduladores de neurotransmissão de dopamina
EA200970704A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ
PE20010402A1 (es) Derivados de 1,5-dihidropirrol-2-ona sustituida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed